What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
The headline refers to a February 28, 2023 report that an FDA official connected with the agency’s Aduhelm review was stepping down. The available report establishes the date and subject, but not enough detail to verify the official’s next role or motives. The broader story is the FDA’s June 2021 accelerated approval of Aduhelm, the process concerns later identified by federal oversight, and the drug’s eventual withdrawal from sale.
What the headline refers to
Ars Technica published a report matching the headline on February 28, 2023. The report’s page is not accessible in the material available for this article, so details beyond the reported departure cannot be confirmed here. In particular, there is no verified basis to attribute a motive to the official or to say that the official personally caused the approval decision. Ars Technica’s February 28, 2023 report
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Rethinking Medications: Truth, Power, and the Drugs You Take | $12.99 | Buy on Amazon |
Why Aduhelm’s approval drew criticism
On June 7, 2021, the FDA granted accelerated approval to Aduhelm (aducanumab), an Alzheimer’s drug. The agency said its decision relied on a reduction in amyloid beta plaques in the brain. FDA treated plaque reduction as a surrogate endpoint—an indirect measure considered reasonably likely to predict clinical benefit—while acknowledging that uncertainty remained about whether the drug would provide that benefit to patients. FDA’s June 7, 2021 explanation
The dispute was not simply about whether the drug changed a biomarker. It involved scientific disagreements, whether plaque reduction was an adequate basis for accelerated approval, the weight given to the FDA advisory committee, and how the agency documented and handled its interactions with the manufacturer. FDA’s decision should be distinguished from a finding that clinical benefit had been conclusively demonstrated: the agency itself described residual uncertainty.
Free tools Windows power users keep installed
One-click scans. No signup required.
#1 Best Overall
What federal oversight later found
A 2024 review by the Department of Health and Human Services Office of Inspector General examined a purposive-plus-random sample of 24 drugs among 278 accelerated approvals. Three drugs in the sample, including aducanumab, raised concerns; 21 did not raise the kinds of concerns associated with those three cases. These are findings about the selected sample, not a population-wide rate or a conclusion that the same problems applied to every accelerated approval. HHS OIG’s 2024 evaluation
Meeting records and sponsor interactions
OIG said FDA administrative files documented 13 meetings with the aducanumab sponsor. Five took place from July 2019 to July 2020. Four other referenced meetings did not have minutes or summaries in the files. OIG also described uncertainty in reconciling FDA’s records with a congressional investigation that cited at least 40 meetings. The gap in documentation is an oversight finding; by itself, it does not establish what was said at undocumented meetings or prove improper intent.
Scope of the process concerns
OIG identified concerns including FDA consideration of analyses outside the sponsor’s original analysis plans and incomplete meeting documentation. The report also discussed the controversy over the scientific basis for approval and advisory-committee input. Its findings focus on aducanumab and two other sampled outliers, rather than establishing that FDA routinely handled accelerated approvals this way.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What happened to Aduhelm afterward
In 2022, Medicare coverage for Aduhelm was limited to patients enrolled in certain clinical trials. In 2024, the manufacturer announced it would stop selling the drug and terminate its confirmatory trial, according to OIG. Aduhelm is therefore not a current treatment option through ordinary commercial sales.
Another Alzheimer’s drug approval does not reverse or continue Aduhelm’s decision. On July 2, 2024, FDA announced approval of Kisunla (donanemab) for adults whose Alzheimer’s disease was initiated at the mild cognitive impairment or mild dementia stage. It is a separate drug and regulatory decision, not evidence that Aduhelm’s approval questions were resolved. FDA’s Kisunla announcement
Quick Recap
Timeline
- June 7, 2021: FDA grants Aduhelm accelerated approval based on amyloid plaque reduction while acknowledging uncertainty about clinical benefit.
- December 2022: Two congressional committees issue an investigation critical of FDA’s aducanumab review, as summarized later by OIG.
- February 28, 2023: Ars Technica publishes the report about an FDA official stepping down.
- 2024: The manufacturer announces it will stop Aduhelm sales and end the confirmatory trial; OIG publishes its retrospective evaluation.
- July 2, 2024: FDA announces approval of Kisunla, a separate Alzheimer’s treatment.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
